ioHepatocytes
Cryopreserved human iPSC-derived cells powered by opti-ox, that are ready for experiments in days. Ideal for hepatotoxicity screening, drug metabolism studies, and disease modeling. Consistent, functional hepatocytes for long-term 2D culture.
Receive your quote directly from the manufacturer.
Powered by opti-ox™ deterministic programming, ioHepatocytes deliver a scalable, highly consistent source of human iPSC-derived hepatocytes that eliminate donor variability.
ioHepatocytes display classic cobblestone morphology with distinctive nuclei and well-defined borders. They express key pan-hepatocyte markers, including ALB, HNF4A, ASGR1, CYP3A4, and present a transcriptomic signature similar to primary human hepatocytes (PHHs).
In 2D monolayer cultures, ioHepatocytes exhibit long-term functional viability exceeding 17 days, characterized by robust albumin secretion and active CYP450 enzymes.
Critically, the cells express key Phase I, II, and III drug metabolism genes. When challenged with known hepatotoxins, they successfully mirror the DILI response of primary human hepatocytes, offering an optimized, human-relevant platform for predictive toxicology, metabolic profiling, and disease modeling.
Predictive iPSC‑derived hepatocytes powering the next wave of translational toxicology
Wednesday, July 15 at 16:00 BST | 17:00 CEST | 11:00 EDT | 08:00 PDT
Early‑stage drug discovery increasingly relies on liver models for physiologically relevant insight, yet many of these systems still lack the reliable and reproducible data needed for confident predictive toxicology. Primary human hepatocytes (PHHs) are the commonly used model for predictive screening of drug‑induced liver injury (DILI); however, their poor longevity in culture, batch variability, and limited availability make it challenging to identify liabilities early. The need for more scalable, consistent and high‑fidelity liver models has never been more critical.
To address these challenges, join Principal Scientist Dr. Gianmarco Mastrogiovanni in this SelectScience® webinar as he demonstrates how scalable, consistent ioHepatocytes can be applied for DILI prediction. Using opti‑ox™ deterministic cell programming, these iPSC‑derived hepatocytes achieve the reproducibility, scale and functional maturity needed to overcome PHH limitations, and Dr. Mastrogiovanni will show how their performance supports more reliable early ADME‑toxicology and safety assessment.
Register now to discover how reliable, high‑performance ioHepatocytes can accelerate smarter, safer drug development and reshape the future of early‑stage toxicology.
Certificate of attendance
If you attend the live webinar, you will automatically receive a certificate of attendance, including a learning outcomes summary, for continuing education purposes. If you view the on-demand webinar, you can request a certificate of attendance by emailing editor@selectscience.net.
Webinar details
- Cost: Free to attend
- Location: Online
- Duration: 60 minutes
Registration is required to secure your place. If you register but can’t attend live, you will receive a link to the on-demand recording once it becomes available.
